BUFFALO, N.Y. – On April 28, the University at Buffalo, as
part of the Roadster Clinical trial, performed a procedure for the
first time on the east coast known as the Silk Road system —
a less-invasive surgical treatment of carotid artery disease for
Adnan Siddiqui, MD, associate professor of neurosurgery in the
UB School of Medicine and Biomedical Sciences, and a patient who
was treated are available today by phone to speak with media about
the importance of this procedure.
Media arrangements and inquiries: Ellen Goldbaum, in the Office
of University Communications at 716-645-4605.
The most common treatment for severe carotid artery
disease—when the artery gets blocked with a buildup of
plaque—has been a surgery called carotid endartarectomy
(CEA), which involves making an incision about 4 ½ inches
long in the neck to access the affected artery, open it and remove
However, for patients who are considered at high risk for
surgical treatment because of age or existing medical conditions,
CEA may not be feasible. A potential complication of CEA surgery is
The Roadster Clinical Trial was originally begun in California
and is underway in the U.S to continue to evaluate the safety of
the Silk Road system. UB’s participation in the study began
in April with four patients who were diagnosed with severe carotid
disease. They were considered too high risk for CEA but qualified
as candidates for the Silk Road system procedure.
The Silk Road system procedure is performed through a much
smaller incision at the neckline just above the collarbone. The
procedure is much safer because it temporarily directs blood,
through a system of tubing, away from the brain to protect against
plaque that may come loose and cause a possible stroke. Blood flows
through the system and any material is captured in a filter.
Filtered blood is then returned through a second tube in the upper
The study is funded by Silk Road Medical, developers of the
Transcarotid Stenting with Dynamic Flow Reversal system.